European Headache Alliance

Tag Archives: Headache

Sad news at EMHA

It is a sad day for the headache world and for the EMHA it is with the greatest sadness that we announce the sudden death of Dr.Paolo Rossi, Board Member and Medical Advisor to EMHA. Paolo was killed in a car accident leaving his work last night. We would like to share in our site…
Read More

Master of Headache Disorder

Copenhagen University is now offering a Master on Headache Disorders. It´s a continuing professional development programme for healthcare professionals. The programme requires a minimum of 6 individual visits to Copenhagen, Denmark over a two-year period: Modules 1 to 4 are organized with an e-learning self-study period followed by one week of face-to-face sessions at University of…
Read More

Lilly Receives Positive CHMP Opinion for Emgality

INDIANAPOLIS, Sept. 21, 2018 Lilly Receives Positive CHMP Opinion for EmgalityTM (galcanezumab) for the Prophylaxis of Migraine in Adults Eli Lilly and Company announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality TM (galcanezumab) for the prophylaxis of migraine in adults who have at least…
Read More

European Civic Prize on Chronic Pain

Active Citizenship Network launch the second edition of the bi-annual research-project at the European level “EU Civic Prize on Chronic Pain - Collection of good practices” with the aim to continue to give evidence on existing good practices in several European countries in terms of the struggle against pain. Aims of the project Giving continuity…
Read More

The #MigrainePose “Trend”

  How can this even be a trend!!!!???? Headache Pose? Migraine Pose? What is this supposed to mean? Migraine is not a pose but a neurological disorder involving nerve pathways and brain chemicals, which leaves completely disabled anyone who suffers an attack for an uncertain period of time. It´s very sad and outrageous that such an important…
Read More

New Aimovig Medication Approved

Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its- kind treatment specifically designed for migraine prevention Jul 30, 2018 Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month. Aimovig is the first…
Read More

Why is migraine still a big mystery to science

Very common especially in women, these intense headaches are still a great medical mystery whose causes are not enlightened. Very common especially in women, these intense headaches are still a great medical mystery whose causes are not enlightened. Migraines are always related to a "simple headache", but they are much more. While "normal" headaches can…
Read More

11.3% of Spanish adolescents suffer from migraine headaches

The journal Cephalalgia – the scientific publication of the International Society of Headaches – has just published a study by members of the Headache Study Group of the Spanish Society of Neurology (SEN) of the Vall D'Hebron University Hospital, whose Objective was to evaluate the prevalence of a headache among the Spanish adolescent population. Carried…
Read More

How to take care of your diet if you suffer migraine

30 DE MAYO DE 2018 If we pay attention to what we eat, we can contribute to keeping headaches as far away from our lives as possible. If you have migraines, you probably know that maintaining a healthy lifestyle and respecting food and sleep schedules are two fundamental elements to keep them under control. But…
Read More

Novartis’ Migraine prevention therapy is closer to being approved

Friday, June 1, 2018, at 15:45 Novartis has announced that the European Medicines Agency (EMA) Committee on Human Use Medicines (CHMP) has recommended Aimovig (erenumab) approval to prevent migraine in adults suffering at least 4 days of migraine per month. The World Health Organization (WHO) has mentioned migraine as one of the top ten causes…
Read More